Summary

Hormonal Contraceptive Market – Scope of Report
TMR’s report on the global hormonal contraceptives market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global hormonal contraceptives market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hormonal contraceptives market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the hormonal contraceptives market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hormonal contraceptives market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hormonal contraceptives market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hormonal contraceptives market.

The report delves into the competitive landscape of the global hormonal contraceptives market. Key players operating in the global hormonal contraceptives market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hormonal contraceptives market profiled in this report.

Key Questions Answered in Global hormonal contraceptives Market Report
• What is the sales/revenue generated by hormonal contraceptives across all regions during the forecast period?
• What are the opportunities in the global hormonal contraceptives market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Hormonal Contraceptive Market – Research Objectives and Research Approach
The comprehensive report on the global hormonal contraceptives market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hormonal contraceptives market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hormonal contraceptives market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Hormonal Contraceptive Market
4. Market Overview
4.1. Introduction
4.1.1. Technology Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Hormonal Contraceptive Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Technology/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Hormonal Contraceptive Market Analysis and Forecast, by Method
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Method, 2017–2031
6.3.1. Oral Contraceptives
6.3.2. Transdermal Patches
6.3.3. Injectable Contraceptives
6.3.4. Intrauterine Contraceptives
6.3.5. Vaginal Rings
6.4. Market Attractiveness Analysis, by Method
7. Hormonal Contraceptive Market Analysis and Forecast, by Hormones
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Hormones, 2017–2031
7.3.1. Progestin Only
7.3.2. Combined Hormones
7.4. Market Attractiveness Analysis, by Hormones
8. Hormonal Contraceptive Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Drug Stores
8.3.2. Gynecology/Fertility Clinics
8.3.3. E-commerce
8.3.4. Others
8.4. Market Attractiveness Analysis, by Hormones
9. Hormonal Contraceptive Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Hormonal Contraceptive Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Method, 2017–2031
10.3.1. Oral Contraceptives
10.3.2. Transdermal Patches
10.3.3. Injectable Contraceptives
10.3.4. Intrauterine Contraceptives
10.3.5. Vaginal Rings
10.4. Market Value Forecast, by Hormones, 2017–2031
10.4.1. Progestin Only
10.4.2. Combined Hormones
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Drug Stores
10.5.2. Gynecology/Fertility Clinics
10.5.3. E-commerce
10.5.4. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Method
10.7.2. By Hormones
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Hormonal Contraceptive Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Method, 2017–2031
11.3.1. Oral Contraceptives
11.3.2. Transdermal Patches
11.3.3. Injectable Contraceptives
11.3.4. Intrauterine Contraceptives
11.3.5. Vaginal Rings
11.4. Market Value Forecast, by Hormones, 2017–2031
11.4.1. Progestin Only
11.4.2. Combined Hormones
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Drug Stores
11.5.2. Gynecology/Fertility Clinics
11.5.3. E-commerce
11.5.4. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Method
11.7.2. By Hormones
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Hormonal Contraceptive Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Method, 2017–2031
12.3.1. Oral Contraceptives
12.3.2. Transdermal Patches
12.3.3. Injectable Contraceptives
12.3.4. Intrauterine Contraceptives
12.3.5. Vaginal Rings
12.4. Market Value Forecast, by Hormones, 2017–2031
12.4.1. Progestin Only
12.4.2. Combined Hormones
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Drug Stores
12.5.2. Gynecology/Fertility Clinics
12.5.3. E-commerce
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Method,
12.7.2. By Hormones
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Hormonal Contraceptive Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Method, 2017–2031
13.3.1. Oral Contraceptives
13.3.2. Transdermal Patches
13.3.3. Injectable Contraceptives
13.3.4. Intrauterine Contraceptives
13.3.5. Vaginal Rings
13.4. Market Value Forecast, by Hormones, 2017–2031
13.4.1. Progestin Only
13.4.2. Combined Hormones
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Drug Stores
13.5.2. Gynecology/Fertility Clinics
13.5.3. E-commerce
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Method,
13.7.2. By Hormones
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Hormonal Contraceptive Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Method, 2017–2031
14.3.1. Oral Contraceptives
14.3.2. Transdermal Patches
14.3.3. Injectable Contraceptives
14.3.4. Intrauterine Contraceptives
14.3.5. Vaginal Rings
14.4. Market Value Forecast, by Hormones, 2017–2031
14.4.1. Progestin Only
14.4.2. Combined Hormones
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Drug Stores
14.5.2. Gynecology/Fertility Clinics
14.5.3. E-commerce
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Method,
14.7.2. By Hormones
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AbbVie, Inc.
15.3.1.1. Company Overview
15.3.1.2. Technology, Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Afaxys, Inc.
15.3.2.1. Company Overview
15.3.2.2. Technology, Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Bayer AG
15.3.3.1. Company Overview
15.3.3.2. Technology, Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Agile Therapeutics
15.3.4.1. Company Overview
15.3.4.2. Technology, Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Merck & Co., Inc.
15.3.5.1. Company Overview
15.3.5.2. Technology, Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Piramal Enterprises Ltd.
15.3.6.1. Company Overview
15.3.6.2. Technology, Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Pfizer Inc.
15.3.7.1. Company Overview
15.3.7.2. Technology, Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. HLL Lifecare Limited
15.3.8.1. Company Overview
15.3.8.2. Technology, Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview